Evidence map›Paper›PMID 42201945›Full record

ArticlePLoS neglected tropical diseases2026

Feasibility study of an AI-powered mobile app to support cutaneous leishmaniasis diagnosis in the Brazilian Amazon.

Karina Lumy Okita, Thamires Bastos Pinheiro, Livia Oliveira-Ciabati, Breno Dos Santos Alves, Pedro Luis Gil Bonett, Elinea Liborio Fragoso, Eddy Jens Rivero-Zavala, Antonio Joaquim Fernandes, Gustavo Costa Souza, Jorge Ewerton Dos Santos Sales and 3 more

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Karina Lumy OkitaHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.ORCID https://orcid.org/0000-0003-0651-1277
Thamires Bastos PinheiroProgram in Applied Sciences in Dermatology at the State University of Amazonas, Manaus, Amazonas, Brasil.
Livia Oliveira-CiabatiHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Breno Dos Santos AlvesHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Pedro Luis Gil BonettHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Elinea Liborio FragosoHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Eddy Jens Rivero-ZavalaHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Antonio Joaquim FernandesHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Gustavo Costa SouzaHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.
Jorge Ewerton Dos Santos SalesFundação Hospitalar Alfredo da Matta, Manaus, Amazonas, Brasil.
Maria das Graças Vale Barbosa GuerraProgram in Applied Sciences in Dermatology at the State University of Amazonas, Manaus, Amazonas, Brasil.
Jorge Augusto de Oliveira GuerraProgram in Applied Sciences in Dermatology at the State University of Amazonas, Manaus, Amazonas, Brasil.
Isabelle CarvalhoHealth Innovation Techcenter, Hospital Israelita Albert Einstein: Sociedade Beneficente Israelita Brasileira Albert Einstein, São Paulo, São Paulo, Brasil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCutaneous leishmaniasis (CL) remains a major public health challenge, especially in Brazil's Amazon, where environmental and economic pressures sustain transmission. Delayed diagnosis drives morbidity, stigma, and costs. Community health workers are pivotal yet under-equipped for early triage. Artificial intelligence, effective in dermatologic imaging, is underused for CL; feasible, offline clinical tools could accelerate referral and timely care. This study aimed to evaluate the feasibility of an AI-assisted tool for early CL triage in the Brazilian Amazon by: (i) developing an AI model for CL identification from clinical skin lesion images; (ii) integrating the model into an offline-optimized mobile application for resource-limited settings; and (iii) conducting initial, real-world clinical validation.

methodsExploratory, IRB-approved feasibility study. Retrospective images from Brazilian Amazon sites informed a two-stage AI pipeline (lesion segmentation+classification) integrated into an offline mobile app. Multicenter validation in ideal- and real-world scenarios. Primary metric AUC-ROC; secondary sensitivity/specificity. One-sided tests: AUC-ROC [Formula: see text]0.70; ideal-world sensitivity [Formula: see text]0.75.

resultsFor the Classification Model, 64 images were assigned to the test set while 1,160 were used for training and validation (80:20 split), with DenseNet121 yielding the highest accuracy of 0.88. The full AI pipeline (Segmentation and Classification models) achieved an accuracy of 0.81, an F1-score of 0.80, an AUC-ROC of 0.90, and a sensitivity of 0.76. In the ideal-world analysis, sensitivity reached 0.92, the F1-score was 0.84, and specificity was 0.42.

conclusionsWe demonstrate the feasibility of an offline, AI-assisted mobile tool to support triage and referral for cutaneous leishmaniasis in the Brazilian Amazon. Performance reflects preliminary, descriptive point estimates from an initial diagnostic accuracy assessment and should be interpreted with caution; the tool is not intended for standalone diagnosis. Next steps include prospectively powered clinical validation, usability refinements, and regulatory evaluation, including alignment with ANVISA requirements in Brazil. Overall, this work represents an initial step toward closing the gap in clinically supported diagnostic tools for neglected tropical diseases in resource-constrained settings.

Indexed as

Artificial IntelligenceLeishmaniasis, CutaneousMobile ApplicationsAdolescentAdultBrazilChildFeasibility StudiesFemaleHumansMaleMiddle AgedRetrospective StudiesSensitivity and SpecificitySkinYoung Adult

Identifiers

PMID42201945
PMCPMC13215602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.